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Abstract
Purpose and methods As a part of reviewing the
Multinational Association of Supportive Care in Cancer
(MASCC) antiemetic guidelines in Perugia in 2009, an
expert group identified directions for future antiemetic
research.
Results and conclusions In future trials, the prediction of
nausea and vomiting may combine algorithms based on
observed prognostic factors relating to the patient and the
anticancer therapy, the identification of the genes that code for
receptors, and pharmacogenetic studies of the metabolism of
drugs. Design issues for future trials include standardising the
emetic stimulus across studies and finding the minimum
tolerated effective dose and schedule of an antiemetic. Also
control of delayed emesis is not independent of the control of
acute emesis. The full range of side effects and the impact on
global quality of life scores should be part of the routine
assessment of an antiemetic. With current high rates of control
of acute vomiting, future trials will need to consider new
primary endpoints such as nausea, a complex symptom, where
improvement is needed. Economic endpoints should be
incorporated to ascertain the cost benefit of antiemetic
prophylaxis, taking into account the impact of nausea on
work capacity. New antiemetic drugs may be targeted at
different receptors, such as opioid, cannabinoid and peptide
YY receptors. New research is needed into determining the
extent of corticosteroid use. The emetic potential of a range of
newer cytotoxics particularly when used in combinations and
different scheduling, such as prolonged oral dosing of
cytotoxics and use of targeted therapies, are all areas in need
of research. More antiemetic studies are needed in niche areas
such as in patients receiving high dose chemotherapy,
radiation therapy or combined modality therapy. Further
evidence of the efficacy of newer antiemetic agents is required
in children.
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Introduction
In 2009, a meeting was held in Perugia in Italy to revise the
MASCC antiemetic guidelines. Experts review the litera-
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ture and produce guidelines according to the available
evidence or by consensus if the evidence is poor. One
committee is charged with identifying areas where future
research would be most fruitful.
Although the control of both acute and delayed vomiting
after anti-cancer chemotherapy is satisfactory in the majority
of patients due to the combination of a 5-hydroxytryptamine 3
receptor (5-HT3) antagonist, dexamethasone and a neuro-
kinin 1 receptor (NK1) antagonist, there are still specific
areas requiring further research. With gene arrays and
pharmacogenomics, we should have an opportunity to create
better algorithms for predicting emesis. Nausea, a term
which covers subjective feelings, is not controlled as well as
vomiting. Data on emesis risk and the need for antiemetic
prophylaxis have not been well researched with new drugs,
targeted therapies and prolonged oral therapy. New receptors
are targets for new antiemetic drugs and functional imaging
will refine dosing strategies. We need to improve our
creation and dissemination of guidelines.
Prognostic factors
Factors predicting who would vomit after chemotherapy
have been identified over decades of antiemetic studies.
The emetic potential of the drugs in the chemotherapy
regimen, which in turn depends on their doses and
schedules resulted in them being classified into groups of
those with minimal, low, moderate or high risk of causing
emesis if left untreated [18]. The emetic potential of
combinations of drugs were more problematic to classify,
due to the limited data available. For example, the
combination of an anthracycline and cyclophosphamide,
both of which have moderate emetic potential, results in a
regimen of high emetic potential. Furthermore, the emetic
risk classification does not include nausea.
There were also patient characteristics which were
associated with a propensity to experience emesis post
chemotherapy. There was more difficulty controlling post-
chemotherapy emesis in females, younger patients did not
respond as well to antiemetics, and a history of prior
alcohol intake of greater than 100 g/day was associated
with less emesis following cisplatin chemotherapy [10, 38,
42, 43]. The reason for these observations could still be a
useful area for further research. It is noteworthy, that
addition of the NK1 receptor antagonist, aprepitant, to a
combination of ondansetron and dexamethasone, seemed to
negate the adverse prognostic effect of female gender on
the prevention of chemotherapy-induced vomiting. With
addition of aprepitant 66% of women and 69% of men were
protected from emesis and did not need rescue medication
after cisplatin-based chemotherapy, whereas only 41% of
women as compared to 53% of men were protected without
aprepitant [17].The physiological or pharmacological
mechanisms of such gender differences, for example the
influence of hormonal status, would be worth exploration.
Other factors being explored, are the susceptibility to
motion sickness or the setting of the chemotherapy [32].
Furthermore, low emotional or role functioning, past
history of morning sickness, anxiety, expectations for
developing nausea/vomiting during chemotherapy or
vestibular dysfunction have also been identified as key
risk factors [31, 37, 50]. Further psychosocial factors need
to be explored, as does the issue of whether the
expectation of nausea and vomiting is correlated with its
occurrence [19, 35].
Although clinical decision-making may be aided by
creating an algorithm based on these prognostic factors for
emesis, new genetic factors being investigated may make
the prediction of emesis and selection of antiemetics and
their doses more accurate. The emergence of gene array
technology identifying the genes coding for the 5-HT3 and
NK1 receptors may allow clinical correlations and more
rational selection of antiemetic regimens for patients. For
example, patients with genetic variations in the 5-HT3B
receptor gene might respond differently to antiemetic
treatment with the 5HT3 receptor antagonists [46].
Pharmacogenetic studies investigating functional genetic
polymorphisms involving serotonergic, dopaminergic and
neurokinin systems may allow more rational drug and dose
selection for individual patients. For example, the efficacy
of antiemetic treatment with some 5HT3 receptor antagonists
(e.g. tropisetron) depends on cytochrome P-450 2D6
(CYP2D6) genotype, and rapid and ultrarapid metabolisers
could be undertreated [23]. Ultrarapid metabolisers could,
however, benefit from treatment with a 5-HT3 antagonist not
dependent of the CYP2D6 enzymes (e.g. granisetron).
Design issues in clinical trials
The randomised controlled double blind parallel design has
been the gold standard for antiemetic studies, and will
continue to be so, but there are issues to be resolved in the
design of future trials. For example, the studies will have to
be controlled for the new prognostic factors suggested
above.
Another issue is standardising the emetic stimulus across
studies. Cisplatin at greater than 50 mg/m2 has been the
standard upon which regimens of high emetic potential
have been based, but there has been confusion about the
combination of an anthracycline and cyclophosphamide, two
drugs of moderate emetic potential, which in combination
become a regimen of high emetic potential.
When studying delayed emesis the response rate to an
antiemetic may be influenced by the control of the acute
phase of emesis. In the pivotal studies of aprepitant as part
of a triple antiemetic regimen with a 5HT3 receptor
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antagonist and dexamethasone, the NK1 receptor antagonist
was always used in the acute phase and then continued to
cover the delayed phase. Palonosetron with its longer
duration of action also was commenced in the acute phase.
The response in the acute phase does influence the control
of delayed emesis [2].
Side effects that are particularly due to a new antiemetic
can be difficult to ascertain when antiemetics are given in
combinations and the side effects of the cytotoxic therapy
are also present. It is important to broadly record side
effects so that unexpected effects are not missed. It is only
in recent trials, for example, that a link between the use of
aprepitant and increases in neutropenia and febrile neutro-
penia have been reported although this has not been
confirmed in other studies [13]. The measurement of
quality of life gives an overall assessment of the impact
on the antiemetic on the wellbeing of the patient. This is
particularly important not only because it serves to balance
the efficacy and toxicity of the antiemetic but also because
emesis impacts on other aspects of quality of life such as
fatigue, appetite and sleep disturbance [26].
With response rates in acute vomiting approaching 90%
in chemotherapy-naïve patients with triple antiemetic
prophylaxis, it will be increasingly difficult to demonstrate
a clinically meaningful benefit for a new agent looking at
the first course of chemotherapy only. Therefore it can be
useful to monitor the entire course of chemotherapy (4–6
cycles), when a new drug is investigated. The cut off for
clinically meaningful improvement in patient reported
outcomes has been suggested as 10%, with the lowest
estimate being 7% [7, 36]. Different endpoints in future
studies are desirable. The most obvious of these is nausea
which is not as well controlled as vomiting [30]. Nausea is
an entity which encompasses different subjective and
objective experiences and needs to be better defined in
order to address it properly in future studies [40].
In time it may be possible to incorporate functional
endpoints such as the effective blockade of receptors as
demonstrated by PET scan which may allow early
prediction of efficacy, as discussed below.
Economic endpoints should be part of randomised trials
of new antiemetics and combinations. These are best
measured prospectively and design issues discussed with
health economists. It is important to ascertain the minimal
effective dosing and scheduling of antiemetics [5, 25, 52].
This not only improves the therapeutic index but the cost
efficacy ratio.
Other design issues include the measurement of efficacy
over multiple cycles to see if there is any change in efficacy
of the antiemetic regimen over time. The methodological
challenges of evaluating antiemetic therapy over multiple
cycles are well documented [14]. These studies are best
done in patients with tumour types which will minimise the
dropout rate. Patients dropping out can change the balance
of prognostic factors over time. Also, statistical techniques
need to account for the antiemetic efficacy in a particular
cycle being influenced by the response in the previous
cycle [42]. There is also a need to specifically explore
regimens which will rescue that small percentage of
patients who do not respond to the established antiemetics.
Such patients can be pre-randomised to a particular rescue
regimen if required or entered onto a study if they fail to
respond to an antiemetic regimen given as prophylaxis prior
to the first cycle of therapy.
Usage of corticosteroids
Corticosteroids such as dexamethasone are mentioned by
guidelines as prophylaxis against chemotherapy of low
emetic potential when administered as monotherapy, and
are used to prevent vomiting and nausea in either
chemotherapy of moderate or high emetic potential due
to their synergistic efficacy in combination with other
antiemetics. In guidelines, the scheduling and dosing of
corticosteroids is tailored by taking into account the
therapeutic setting and not the patient’s characteristics,
which are of importance. However, the clinician must
consider that their administration may be associated with
a range of side-effects, which may increase when
administered as part of multiple-day antiemetic regimens
[48]. A recent survey investigating moderate to severe
side-effects associated with dexamethasone administered
for prophylaxis against delayed CINV after MEC included
insomnia (45%), gastrointestinal symptoms (27%), agitation
(25%), increased appetite (18%), weight gain (17%), skin
rash (15%) and depression (7%) [48]. For these reasons,
there is a particular interest in reducing their administra-
tion in certain clinical situations and/or in certain subsets
of patients. Thus recently one double-blind study and one
open-label study in patients receiving palonosetron plus
dexamethasone on day 1 randomly assigned to receive
either placebo or dexamethasone on days 2 and 3 have
shown that there is an opportunity to reduce the total
corticosteroid dose with no loss of efficacy in delayed
MEC, although some patients experience an increase of
nausea on some periods of observation [1, 6].
It should be noted that present guidelines, based on the
fact that steroids were not used on days 2 and 3 of
aprepitant containing antiemetic regimes when patients
received AC like chemotherapy do not advocate the use
of steroids for prevention of delayed nausea, while the
studies showed that up to 50% of the patients suffered from
nausea. This paradox will need further study in the setting
of single day antiemetic regimens, which are highly
effective in emesis control, but also seem to lose on control
of nausea over several days [16].
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New antiemetics
There are some drugs such as olanzapine which act on
multiple receptors and are only just being investigated for
post-chemotherapy emesis. Olanzapine is a thienobenzo-
diazepine which acts on multiple receptors including
dopamine, serotonin, adrenergic, muscurinic and histamine
receptors and has shown antiemetic activity in small studies
with serotonin antagonists and steroids in both acute, and
delayed emesis [33, 44].
The advent of the NK1 receptor antagonists demonstrated
the utility of functional imaging of NK1 receptors by PET
scan [15]. Techniques are evolving which can not only
visualise where the receptors are, but quantitate them, and
this will enable non-invasive methods of studying the
binding of NKI receptor antagonists [34]. Such functional
imaging can be used in developing new agents such as NK1
receptor antagonists which bind with higher affinity and will
have a longer duration of action [21]. PET scans with
appropriate labelled markers can be used to investigate
different neurotransmitters and address issues like the
optimal duration of receptor occupancy for antiemetic
efficacy or the relative importance in acute or delayed
emesis of central as compared to peripheral receptors.
There are still many possibilities for new anti-emetic
agents to be developed as new receptor families are further
investigated. The mu opioid receptors, for example, may
mediate an antiemetic response in humans [41]. The
cannabinoid CB1-receptor agonists possess broad-spectrum
antiemetic activity in animal models in both chemotherapy
and radiation therapy induced emesis [8, 47]. The synthetic
cannabinoids nabilone and levonantradol have proven
antiemetic activity in humans but side effects limit their
usefulness [45, 49]. Studies of peptide YY and its analogues
and its binding sites may result in a new class of antiemetic
strategies [24].
New research
Nausea
We have suggested nausea as one of the primary endpoints
for future studies because it has a much higher impact on
daily living than vomiting and because it will be possible to
more easily measure improvements but is not well
controlled by present antiemetic regimens. Nausea is often
present without the presence of vomiting, and hence these
two symptoms are related but distinct phenomena. However,
the subjective side effect of nausea in its own right needs
further study. As a side effect it has the three components of
severity, duration and frequency, which should be reported.
However nausea is a subjective sensation which can only be
reported by the patients who have been found to be reporting a
complex array of symptoms ranging from anorexia to
indigestion with nausea perhaps being only part of a symptom
cluster [30]. More qualitative research is required to define
the range of symptoms that patients report as nausea, so that
a range of treatments in addition to antiemetics can be
employed if necessary. A recent study in rats found that
hypothalamic ghrelin decreased markedly 24–48 h after
cisplatin and that intracerebroventricular injection of ghrelin
was able to reverse the cisplatin-induced decrease in food
intake. Furthermore the decrease in ghrelin secretion seemed
to be caused by stimulation of 5-HT2 receptors, because a
5-HT2 receptor antagonist was able to enhance ghrelin
secretion and to suppress cisplatin-induced anorexia [51].
Nausea may have different targets that may require the
identification of new and unique receptor pathways. This
may provide insights into other symptoms such as
anorexia which may cluster with it.
Time course and severity of emesis, secondary antiemetic
and new drug delivery systems
It should be routine in the development of new anticancer
agents that the intensity and duration of emesis is
determined to optimise the use of prophylactic antiemetics.
More recent drugs in common usage such as oxaliplatin and
pemetrexed require better characterisation of their emetic
potential in combination therapies, as indeed other
commonly used combination chemotherapy agents.
Hence there is a need for more observational prospective
data characterising the course of nausea/vomiting over
several cycles to obtain more information on the emetic
potential of combination drugs, which will help in an
improved classification of the emetic potential of these
drugs. This is also true for low and minimally emetic
chemotherapy, where the data available is insufficient to
guide practice and a particular focus should be directed
to antiemetic control in patients receiving such chemotherapy;
the assessment of the effectiveness of some ‘secondary’
antiemetics in this lower emetic risk group may be
appropriate. Furthermore, the role of ‘secondary’ antiemetics
(i.e. benzodiazepines, anticholinergics etc.) in combination
with ‘standard’ antiemetics or as rescue medications is not
well established, although they are used very frequently in
everyday practice, and this may be another area of research
focus in the future. An improved generation of such secondary
antiemetics may also be a future research endeavour.
Cytotoxic drugs delivered by prolonged oral administration
such as capecitabine or temozolomide have not had the time
course of their associated emesis well documented, and no
evidence based recommendations for prophylactic antiemetics
can be recommended. A similar situation exists for targeted
therapies such as imatininb, which are also administered by
prolonged oral dosing. Recording the emesis will require
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modification of the patient diary tools which were initially
designed for intermittent dosing. Assessment of nausea/
vomiting should be improved in future studies, and the use of
well validated and sensitive multidimensional tools should be
carefully considered. Use of the same tool across studies will
facilitate in the future the possibility of comparisons. MASCC
has developed and validated such a tool [27] and a
comprehensive review of the quality and psychometric
properties of all tools available to date to measure nausea/
vomiting is available [4].
While the intravenous and oral administration of
antiemetics is well established, other delivery systems,
such as the granisetron trasdermal patches [3] which are
available in some countries such as the USA and Australia,
may offer more patient choice, can be convenient, reduce
pill counts and be particularly useful where compliance to
medication is low, where there are swallowing difficulties
or where oral absorption may be compromised. Such
delivery systems need further research.
Niche groups
There are specific treatment groups where evidence is still
required about the optimal antiemetic therapy. Patients
receiving high dose chemotherapy prior to haemopoietic
rescue or multiple day chemotherapy of high emetic
potential require better control of emesis. Children’s
responses to antiemetic combinations should not just be
extrapolated from adult studies, because they have a
different propensity to vomit, are receiving different
regimens, and may respond differently to various classes
of antiemetics. The elderly people with cancer should be
a special focus of future antiemetic research, considering
their comorbidities, polypharmacy, self care abilities,
costs, decreased renal and hepatic function affecting
drug metabolism and excretion [20].Finally there is a
great need for further research into the emesis associated
with patients receiving radiation therapy with multiple
doses and multiple fields, with and without concomitant
chemotherapy.
Non-pharmacological adjuvant interventions
While the views of clinicians on the use of non-
pharmacological approaches to the management of nausea/
vomiting may be mixed, such use as adjuvants to antiemetics
may lead to an improved control of symptoms. There is strong
evidence that electroacupuncture can significantly improve
chemotherapy related nausea/vomiting [12] and that use of
acupressure wristbands can have a protective effect in
chemotherapy-induced [12, 28] and radiotherapy-induced
nausea/vomiting [39], although the acupressure results are
mixed and their role as single antiemetic interventions in
low/minimally emetogenic chemotherapy is unclear. Other
potential useful non-pharmacological interventions include
hypnosis, dietary management or distraction (particularly in
children) that have shown promise, but more concrete
evidence from randomised trials is necessary. Cognitive
behavioural interventions are appropriate for the manage-
ment of anticipatory nausea/vomiting, and indeed recom-
mended by MASCC guidelines, although studies in other
areas of antiemetic control are almost nonexistent and our
understanding of the effects of such treatments needs
improvement.
Guidelines
Studies in new methodologies for guidelines including
literature searching, consulting, disseminating and updating
are needed. Antiemetic guidelines are published by several
groups including MASCC, ASCO and NCCN [22]. The
differences in the guidelines often relate to when they
are updated and therefore encompass the latest literature.
There is very little evidence that has been collected on
the efficacy of the dissemination of antiemetic guide-
lines or their uptake, and their subsequent impact on
clinical practice although a prospective study has
provided some initial evidence that patients receiving
antiemetics based on such guidelines had an improved
control of nausea/vomiting compared to those who did
not receive guideline-consistent antiemetics, and also
there was significant cost savings in the guideline
consistent group [29]. A few trials indicate that only
around 50% of patients receive antiemetic prophylaxis as
recommended by guidelines. Lack of implementation
may be one of the greatest obstacles to effective
prophylaxis of nausea and vomiting, because patients
do better, when they are receiving guideline recommen-
ded antiemetic therapy [11]. More research, however, is
required in this area.
MASCC has taken a multinational approach and has
standing committees responsible for sections of the guide-
lines, which can be updated on the web-based version every
6 months, whilst a major revision occurs in an intensive
review process every 4 years.
A fruitful research area which is being explored by
Cancer Council Australia for guidelines in general, is the
use of a Wiki platform. This would allow for wide
consultation and dissemination, and guidelines could be
updated as new evidence becomes available. It is possible
to search the literature electronically for antiemetic trials
which could be fed as tare into the wiki as they are
published for an expert panel’s comments and decision
about whether the new evidence warrants a change in the
guidelines. Research will be required to see if this is a cost
effective method for keeping guidelines constantly updated.
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Conclusions
Despite the success of the two new classes of antiemetic
drugs, the 5HT3 receptor antagonists and the NK1 receptor
antagonists in preventing acute and delayed post chemo-
therapy vomiting there is still much to be achieved in the
prediction and treatment of emesis. The understanding of
the nature of nausea and more trials to discover how best to
control it, are still required. All new drugs and targeted
therapies should have their emetic potential defined and the
control of emesis with high dose and prolonged oral
scheduling requires new studies. More antiemetic trials are
needed for radiation induced emesis and in the paediatric
age group. Furthermore, combined chemoradiation has
become standard therapy of many cancer diseases and
randomised antiemetic trials are highly warranted in this
setting. The potential of new antiemetics targeted at
different receptors such as opioid or mu receptors may see
emesis continue to be perceived as less of a problem for
patients facing chemotherapy [9].
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